Invesco Ltd. Has $29.81 Million Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Invesco Ltd. decreased its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 10.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,671,386 shares of the company’s stock after selling 425,376 shares during the period. Invesco Ltd. owned approximately 5.37% of Phathom Pharmaceuticals worth $29,812,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PHAT. Jennison Associates LLC increased its holdings in shares of Phathom Pharmaceuticals by 20.4% in the fourth quarter. Jennison Associates LLC now owns 7,062,507 shares of the company’s stock worth $57,348,000 after acquiring an additional 1,196,118 shares in the last quarter. State Street Corp increased its position in shares of Phathom Pharmaceuticals by 17.5% during the third quarter. State Street Corp now owns 922,788 shares of the company’s stock worth $16,684,000 after acquiring an additional 137,539 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Phathom Pharmaceuticals during the fourth quarter worth $3,701,000. Barclays PLC boosted its stake in Phathom Pharmaceuticals by 366.0% in the 3rd quarter. Barclays PLC now owns 57,807 shares of the company’s stock worth $1,044,000 after purchasing an additional 45,402 shares during the period. Finally, Rhumbline Advisers increased its holdings in Phathom Pharmaceuticals by 10.0% during the 4th quarter. Rhumbline Advisers now owns 55,968 shares of the company’s stock worth $454,000 after purchasing an additional 5,110 shares in the last quarter. Institutional investors own 99.01% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on PHAT shares. HC Wainwright restated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research report on Wednesday, April 9th. Craig Hallum reaffirmed a “buy” rating on shares of Phathom Pharmaceuticals in a research report on Friday, March 7th. Cantor Fitzgerald upgraded Phathom Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, February 25th. Finally, Guggenheim reissued a “buy” rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, April 2nd. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $21.83.

Insider Transactions at Phathom Pharmaceuticals

In other news, insider Terrie Curran sold 19,109 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $125,928.31. Following the transaction, the insider now owns 360,465 shares of the company’s stock, valued at approximately $2,375,464.35. This represents a 5.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Azmi Nabulsi sold 7,886 shares of Phathom Pharmaceuticals stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $51,968.74. Following the sale, the chief operating officer now directly owns 233,390 shares of the company’s stock, valued at approximately $1,538,040.10. The trade was a 3.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,256 shares of company stock worth $238,014. 24.10% of the stock is owned by insiders.

Phathom Pharmaceuticals Price Performance

PHAT stock opened at $4.03 on Friday. Phathom Pharmaceuticals, Inc. has a one year low of $3.81 and a one year high of $19.71. The stock has a market cap of $280.64 million, a price-to-earnings ratio of -0.71 and a beta of 0.35. The company has a fifty day moving average price of $5.33 and a two-hundred day moving average price of $8.76.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.